The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About Us
    • Our Team
      • Directors and Officers
      • Our Staff
      • Our Committees
    • Sponsors & Partners
  • Events Calendar
    • Current Events
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • AIRR Community Meeting VIII – Decoding and Recoding Immunity
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Programs
    • Conferences
    • Competitions
      • Huston Award
        • Huston Award submission guidelines
      • Research Competition
      • Science Writing
    • Podcast
    • Webinars
  • Business Intelligence
    • Antibody Discovery & Development
      • Antibody Validation
      • Commercializing Antibody Therapeutics
      • Adaptive Immune Receptor Repertoires
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies to Watch
      • Antibodies in early-stage studies
    • Presentations
  • Learning and Career Center
    • Research Resources
      • Antibodies in late-stage clinical studies
    • Education Resources
    • Society Publications
    • Career Shorts
  • Members
    • Login
    • Note to members
    • Member discount codes
  • Sponsors & Partners
You are here: Home / Monica Fernández-Quintero, PhD & Klaus R. Liedl, PhD, JD

Monica Fernández-Quintero, PhD & Klaus R. Liedl, PhD, JD

Dr. Monica Fernández-Quintero studied Theoretical Chemistry at the University of Innsbruck. During her PhD at the Department of Physiology and at the Department of General Inorganic and Theoretical Chemistry in the group of Bernhard Flucher and Klaus R. Liedl, she demonstrated how molecular dynamics simulations can improve the structure prediction of proteins, i.e., antibodies and ion channels. Dr. Fernández-Quintero received her Bachelor’s degree in 2015, then worked on the dynamics of antibodies, receiving her PhD 2020. She has authored several papers, given talks and presented posters at international conferences featuring various aspects of antibody and T-cell receptor dynamics. She is currently a postdoctoral researcher at the University of Innsbruck, working on the characterization of antibody binding interfaces to facilitate the design of antibodies and to understand antibody pairing preferences. Dr. Fernández-Quintero’s key academic figures are 38 publications, 264 citations and h-index of 10.

Klaus R. Liedl is full professor of Theoretical Chemistry and heads the Department of General, Inorganic and Theoretical Chemistry at the University of Innsbruck. He holds degrees in mathematics and chemistry (1989, 1992) and wrote his PhD (1995) about a QM/MM-algorithm allowing particles to cross the QM/MM-border. He received tenure (1998) for work on nuclear quantum effects in concerted proton transfer reactions. Prof. Liedl’s obtained a degree in law (2003) and wrote a juridical science doctorate thesis (2006) about the European Community Patent and Patent Litigation in Europe. His current research is focused on physics-based understanding of biomolecular interfaces like antibodies, allergens and proteases by computer simulations and quantum mechanics. Klaus R. Liedl’s key academic figures are 380 publications, 9018 citations (<10% self-citations) and h-index of 52.

  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners Old
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals